3 results
Primary ObjectiveEstimate the proportion of subjects fulfilling criteria for symptomatic remission (as defined by Andreasen et al.)* following a transition to 12 months* treatment with flexible-dose PP3M in subjects with schizophrenia previously…
Primary Objective:To evaluate the efficacy of taldefgrobep alfa in participants who are already taking a stable dose of nusinersen or risdiplam or have a history of onasemnogene abeparvovec-xioi, compared to placebo, measured by change in the 32…
This study will evaluate the efficacy and safety of multiple therapies that are selected using somatic alterations and potential predictive biomarkers identified via NGS assays in patients with solid tumors.